Pharsight

Drugs that contain Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir

1. Viekira Pak (copackaged) patents expiration

VIEKIRA PAK (COPACKAGED)'s oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501238 ABBVIE Anti-infective agents and uses thereof
Dec, 2028

(4 years from now)

US8188104 ABBVIE Anti-infective agents and uses thereof
May, 2029

(5 years from now)

US8642538 ABBVIE Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(5 years from now)

US8420596 ABBVIE Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(6 years from now)

US8691938 ABBVIE Anti-viral compounds
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6037157 ABBVIE Method for improving pharmacokinetics
Jun, 2016

(7 years ago)

US6703403 ABBVIE Method for improving pharmacokinetics
Jun, 2016

(7 years ago)

US7148359 ABBVIE Polymorph of a pharmaceutical
Jul, 2019

(4 years ago)

US7364752 ABBVIE Solid dispersion pharamaceutical formulations
Nov, 2020

(3 years ago)

US8399015 ABBVIE Solid pharmaceutical dosage form
Aug, 2024

(4 months from now)

US8268349 ABBVIE Solid pharmaceutical dosage form
Aug, 2024

(4 months from now)

US9139536 ABBVIE Anti-infective agents and uses thereof
Nov, 2028

(4 years from now)

US9006387 ABBVIE Anti-viral compounds
Jun, 2030

(6 years from now)

US9044480 ABBVIE Compositions and methods for treating HCV
Apr, 2031

(6 years from now)

US8686026 ABBVIE Solid compositions
Jun, 2031

(7 years from now)

US8680106 ABBVIE Methods for treating HCV
Sep, 2032

(8 years from now)

US8466159 ABBVIE Methods for treating HCV
Sep, 2032

(8 years from now)

US8492386 ABBVIE Methods for treating HCV
Sep, 2032

(8 years from now)

US8685984 ABBVIE Methods for treating HCV
Sep, 2032

(8 years from now)

US9629841 ABBVIE Formulations of pyrimidinedione derivative compounds
Oct, 2033

(9 years from now)

US10201542 ABBVIE Formulations of pyrimidinedione derivative compounds
Oct, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2019
New Dosing Schedule(D-163) Apr 22, 2019

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Treatment: Use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection; Treatment of hcv infection using dasabuvir;...

Dosage: TABLET;ORAL

More Information on Dosage

VIEKIRA PAK (COPACKAGED) family patents

Family Patents